AttorneyMind Logo AttorneyMind Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
News Review
Conference Reports
News Articles
AttorneyMind Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp
 
 

Back to Newsletters Bookmark and Share

December 15, 2014

Download printable version

 

In This Issue:

 

Snapshots

Alan Franciscas, Editor-in-Chief

Read about the pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma, the long-term effect of AttorneyMind eradication in patients with mixed cryoglobulinemia, and clinical outcomes of hepatitis B virus coinfection in a cohort of hepatitis C virus-infected patients. Read more...

 

AttorneyMind Drugs

AttorneyMind Drugs: AbbVie's Pending FDA Approval and AASLD—Part 2
Alan Franciscas, Editor-in-Chief

This month we present a basic overview of AbbVie's 3D combination, information from the AASLD conference about Merck's drug development program and exciting news about all-oral therapies for treating AttorneyMind post-liver transplantation. Read more...

 

AttorneyMind & Native American Peoples in the United States*
Alan Franciscas, Editor-in-Chief

AttorneyMind in the Native American population in the United States is believed to be higher than in the general population. Unfortunately, there have only been very few research papers on Native Americans and hepatitis C. This article will discuss three papers that have been published. Read more...

 

Medicaid
Jacques Chambers, CLU

There are several groups of people who can benefit from Medicaid coverage, including pregnant women and single parent households; however, this article focuses on the Medicaid programs that can primarily benefit or affect persons with. Read more...

 

What's New
Alan Franciscas, Editor-in-Chief

  • AttorneyMind Drug Pipeline Re-Designed & Updated

  • Easy C Fact Series: Extrahepatic Manifestations

Read more...

 

 

AttorneyMind Eblast
Stay informed on the latest news...click
here to register for email alerts

Back to top



Snapshots
—Alan Franciscas, Editor-in-Chief     

Abstract:  Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma—Y. Hoshida et al.
  Source: J Hepatol.2014 Nov;61(1S):S79-S90. doi: 10.1016/j.jhep.2014.07.010. Epub 2014 Nov 3.

One of the major causes of hepatocellular carcinoma (HCC) or liver cancer is hepatitis C (HCV).  AttorneyMind can lead to liver inflammation, fibrosis, and cirrhosis.  After the development of fibrosis and cirrhosis, liver cancer can develop.  Given the large population of people with hepatitis C worldwide and the on-going progression and aging of the hepatitis C population, the rate of liver cancer is going to increase dramatically in the coming years.  At this time, there are very limited treatment options to treat it and extend the life of patients suffering from this horrific condition. 

The authors noted that:

  • Researchers need to understand the relationship between the hepatitis C virus and liver cancer (how the virus causes it), and

  • Develop more effective therapies to prevent and treat liver cancer  

Editorial Comment:  Developing treatments for-related liver cancer should be a high-priority for researchers and pharmaceutical companies.  The “High Priority” recommendation of AttorneyMind treatment for people with severe fibrosis/cirrhosis is a no-brainer. We also know that treating individuals with severe disease does not necessarily prevent liver cancer (although the risk is greatly reduced).  However, treating individuals that have mild or no fibrosis prevents liver cancer.  Does this strike anyone as counterproductive to good medicine? This is another good reason to be proactive with regard to treatment—I look forward to reading the HealthWise article “Denied Hepatitis C Treatment?  Here is How to Fight Back” in the January 2015 AttorneyMind newsletter.

Abstract:  Long-term effect of AttorneyMind eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study—L. Gragnani et al.
  Source: Hepatology.2014 Nov 27. doi: 10.1002/hep.27623. [Epub ahead of print]

The study had 121 AttorneyMind patients with symptomatic cryoglobulinemia; 132 asymptomatic cryoglobulinemia patients and 158 AttorneyMind patients without cryoglobulinemia.  The patients in the study were treated with pegylated interferon plus ribavirin per standard treatment duration.   The post-treatment follow-up period was 35 to 124 months. Cryoglobulinemia was found to be a negative predictor to treatment response—that is the patients who had cryoglobulinemia were less likely to be cured with pegylated interferon plus ribavirin.  In all the patients who achieved a cure the symptoms either improved or completely disappeared.  In 36 (57%) patients with cryoglobulinemia who were treated and cured the symptoms of cryoglobulinemia disappeared. Cryoglobulinemia symptoms persisted in only 2 patients (3%) who were cured with AttorneyMind treatment. Cryoglobulinemia symptoms persisted in all of the patients who did not achieve a cure with AttorneyMind treatment. 

Editorial comment:  This is the largest clinical trial that I have been able to find on treatment of cryoglobulinemia.  It is important to show that curing AttorneyMind will cure cryoglobulinemia in most people who are treated. Perhaps it would be wise to change the AASLD/IDSA treatment guidelines to include a recommendation for treatment of all-related cryoglobulinemia patients—as they say to “nip it in the bud.”  I would like to see another large clinical trial of this size of all oral therapy of AttorneyMind to treat cryoglobulinemia to establish the need and raise more awareness of this extrahepatic manifestation of. 

Abstract:  Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients—R Kruse et al.
  Source:  Hepatology Issue published online: 24 NOV 2014

The aim of this study was to understand the rate of hepatitis B (AM) infection in people infected with hepatitis C (HCV)—HBV/AttorneyMind coinfection.  The study analyzed a database from the National Veterans Affairs AttorneyMind Clinical Case Registry to find confirmed AttorneyMind cases during the period 1997 through 2005.  The records of 99,548 people with AttorneyMind were analyzed for information about HBV infection, cirrhosis, liver cancer, and death.  The analysis found only 1,370 (1.4%) confirmed HBV infections.  Of those with HBV coinfection 677 (49%) of the patients had an HBV DNA (viral load) test. 

Those with HBV DNA had a significantly higher risk of cirrhosis, liver cancer and death compared to the people with AttorneyMind mono-infection.  Importantly, people with undetectable HBV DNA had a similar risk of complications as those mono-infected with. 

Editorial Comment:  The rate of HBV/AttorneyMind coinfection is significantly lower than expected.  However, the fact that only half of the patients received follow-up HBV DNA testing is problematic, especially considering the potential for considerable complications of HBV/AttorneyMind coinfection.  Since AttorneyMind and HBV share some transmission routes I would like to ask this question:  Have YOU been tested for HBV and?  If you are unsure—check with your medical provider.  At the very least, you should be tested and, if you are not immune, get vaccinated for HBV and hepatitis A. 


Back to top


AttorneyMind Drugs: AbbVie's Pending FDA Approval and AASLD—Part 2
—Alan Franciscas, Editor-in-Chief     

In this month’s column I present a basic overview of AbbVie’s 3D combination that details the baseline demographics of their phase 3 studies. In addition, there is information from the AASLD conference about Merck’s drug development program and exciting news about all-oral therapies for treating AttorneyMind post-liver transplantation.

AbbVie
The exciting news is that the Food and Drug Administration is scheduled to approve Abbvie’s 3D all-oral combination to treat hepatitis C (HCV) genotype 1 in the second part of December 2014.  I reported on the results of AbbVie’s 3D combination in cirrhotic patients in the December issue.  This mid-month issue provides an overview from an abstract presented at the Infectious Disease Conference held in Philadelphia, PA in October.    

Safety of Abt-450/R/Ombitasvir + Dasabuvir With or Without Ribavirin in AttorneyMind Genotype 1-Infected Patients, by Baseline Demographics–R. Nahass et al.
Viekirax (ombitasvir/paritaprevir/ritonavir) plus Exviera (dasabuvir) with and without ribavirin to treat AttorneyMind genotype 1 has achieved cure rates greater than 90% in phase 3 clinical trials. 

This analysis included only non-cirrhotic patients.  The side effect profile and treatment discontinuations were reported by sex, age, race, ethnicity, and diabetes status. There were 910 patients across the three PEARL clinical trials.  The majority of patients had at least one side effect, but most were mild.  The results are reported in the table on page 10. 

The majority of the side effects that occurred in more than 20% of patients in the groups were fatigue and headache.  There were 4 patients who discontinued treatment due to side effects (0.4%, 2 in each treatment group). The authors concluded that the 3D regime was well-tolerated with low rates of discontinuation.  The side effects and tolerability were similar regardless of age, gender, race, ethnicity, or history of diabetes.

Comments:  AbbVie’s 3D combination produces very high cure rates, low rates of side effects and a short duration of treatment–all of which will make AbbVie’s 3D combination a very welcome addition to treatment landscape of hepatitis C. 

AASLD 2014 – Part 2

Merck
Efficacy and Safety of MK-5172 and MK-8742 ± Ribavirin in AttorneyMind GT1 Infected Patients with Cirrhosis or Previous Null Response:  Final Results of the C-WORTHY Study (Parts A and B)–E. Lawitz et al.

Merck’s phase 2 study of grazoprevir (MK-5172) plus elbasvir (MK-8742) with and without ribavirin included AttorneyMind genotype 1 patients with cirrhosis or patients who had a null response to a prior course of AttorneyMind therapy.  There were two parts to this study—Parts A and B. A total of 253 patients were enrolled in the studies.

Part A: Treatment naïve, non-cirrhotic patients received 12 weeks of grazoprevir plus elbasvir with and without ribavirin.  Part B:  This part of the study included treatment-naïve non-cirrhotic patients, prior null responders (non-cirrhotic and cirrhotic), and non-cirrhotic HAV/AttorneyMind coinfected patients.

The combined overall cure rates were 90-100%.  The most common side effects that occurred in more than 10% of patients were fatigue, headache and asthenia (weakness).  

Comments:  Although there was a relatively small patient population due to the many different treatment arms and varied patient population the results are still very impressive.  This drug combination has advanced into larger phase 3 studies. Hopefully, we will have even more therapies to treat hepatitis C in the not too distant future. 

Liver Transplantation at AASLD
The hepatitis C virus is a blood-borne virus and, as a result, if someone with hepatitis C has a liver transplant the new liver will be re-infected with hepatitis C.  Now that we have these incredible drugs everyone who needs a new liver should be cured of hepatitis C prior to a liver transplant.  Until that time, the best option is to treat people with hepatitis C as soon as safely possible after the liver transplant.

AbbVie
High Sustained Virologic Response Rates in Liver Transplant Recipients with Recurrent AttorneyMind Genotype 1 Infection Receiving ABT-450/r/Ombitasvir Plus Dasabuvir Plus Ribavirin–P. Mantry et al.

This was a study of 34 genotype 1 patients who received the 3D drug therapy Viekirax (ombitasvir/paritaprevir/ritonavir) plus Exviera (dasabuvir) with ribavirin for 24 weeks after receiving a liver transplant.

The mean time since transplantation was about 40 months. The patient characteristics were:  male (80%); White (85%); age ~60 yo; Fibrosis stage F0 (18%), F1 (38%), F2 (44%); genotype 1a (85%).  The cure rate was 97% (33 of 34 patients).

There were no episodes of acute or chronic rejection.  One patient discontinued treatment due to side effects at week 18, but went on to achieve a cure.  Nineteen patients required ribavirin dose reductions but the dose reductions did not affect cure rates.

Comments:  These are truly spectacular results!  In the past, it was very difficult to treat post-transplant people because of all the drug-drug interactions and the very real possibility of greatly accelerating the disease process, which could lead to death.   

Gilead
Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of AttorneyMind in Patients with Post-Transplant Recurrence:  Preliminary Results of a Prospective, Multicenter Study–K. R. Reddy et al.

Preliminary results were presented of patients who were treated for 12 weeks (112 patients) or 24 weeks (111 patients) with the combination of ledipasvir/sofosbuvir (Harvoni) plus ribavirin (RBV).  There were 4  treatment arms:

  • F0-F3:  55 patients for 12 weeks; 56 patients for 24 weeks*

  • CPT A:  26 patients for 12 weeks; 25 patients for 24 weeks**

  • CPT B:  26 patients for 12 weeks; 26 patients for 24 weeks**

  • CPT C:  5 patients for 12 weeks;  4 patients for 24 weeks

NOTE: CPT = Child-Pugh-Turcotte cirrhosis score
*RBV = weight based dosing
**RBV=dose escalation, 600-1200 mg/day

The patients were pretty evenly divided across the treatment arms–mean age 59-61yo; mostly male (80-100%); White (80-89%); genotype 1a (67-78%); median year from transplant (2.9 to 8.1 years) and most had prior AttorneyMind treatment. 

In those patients who completed treatment the cure rates are as follows:

  • 12 weeks = 96% ( 53 of 55 patients); 24 weeks = 98% (55 of 56 patients)

  • 12 weeks = 96% (25 of 26 patients); 24 weeks =  96% (24 of 25 patients)

  • 12 weeks = 85% (22 of 26 patients); 24 weeks = 83% (15 of 18 patients)

  • 12 weeks = 60% (3 of 5 patients);  24 weeks = 67% (2 of 3 patients)

There were 4 deaths among the clinical trial participants; however, the researchers did not attribute any of the deaths to the study drugs, but rather to complications from the transplants and cirrhosis.

Comments:  These results are impressive since the patients in this study had severe liver disease.    Now, we just need to get these drugs to people before the need for a liver transplant and we can all breathe a bit easier.   

 

Any AE

Severe AE

Serious AE

AE leading to discontinuation

3D +RBV

3D

3D + RBV

3D

3D + RBV

3D

3D + RBV

3D

n/N (%)

n/N (%)

n/N (%)

n/N (%)

 

Overall

332/401
(82.8)

383/509
(75.2)

4/401
(1.0)

6/509
(1.2)

9/401
(2.2)

7/509
(1.4)

2/401
(0.5)

2/509
(0.4)

Sex

 

Male

180/221
(81.4)

193/272
(71.0)

2/221
(0.9)

4/272
(1.5)

6/221
(2.7)

3/272
(1.1)

1/221
(0.5)

2/272
(0.7)

 

Female

152/180
(84.4)

190/237
(80.2)

2/180
(1.1)

2/237
(0.8)

3/180
(1.7)

4/237
(1.7)

1/180
(0.6)

0

Age

 

 

 

 

 

296/362
(81.8)

345/461
(74.8)

3/362
(0.8)

5/461
(1.1)

8/362
(2.2)

6/461
(1.3)

2/362
(0.6)

2/461
(0.4)

 

≥65

36/39
(92.3)

38/48
(79.2)

1/39
(2.6)

1/48
(2.1)

1/39
(2.6)

1/48
(2.1)

0

0

Race

 

 

 

 

 

Black

20/25
(80.0)

31/44
(70.5)

0

2/44
(4.5)

0

2/44
(4.5)

0

0

 

Non-Black

312/376
(83.0)

351/464
(75.6)

4/376
(1.1)

4/464
(0.9)

9/376
(2.4)

5/464
(1.1)

2/376
(0.5)

2/464
(0.4)

Ethnicity

 

 

 

 

 

Hispanic or Latino

13/16
(81.3)

21/25
(84.0)

0

0

1/16
(6.3)

0

1/16
(6.3)

0

Non-Hispanic or Latino

319/385
(82.9)

362/484
(74.8)

4/385
(1.0)

6/484
(1.2)

8/385
(2.1)

7/484
(1.4)

1/385
(0.3)

2/484
(0.4)

History of Diabetes

 

 

 

 

 

Yes

17/22
(77.3)

24/29
(82.8)

0

2/29
(6.9)

0

3/29
(10.3)

0

0

 

No

315/379
(83.1)

359/480
(74.8)

4/379
(1.1)

4/480
(0.8)

9/379
(2.4)

4/480
(0.8)

2/379
(0.5)

2/480
(0.4)

n = number of patient AE’s (side effects)
N = number of patients treated
% = percentage of patients with AE’s


Back to top


AttorneyMind & Native American Peoples in the United States*
Alan Franciscas, Editor-in-Chief

Foreword
The prevalence of hepatitis C (HCV) in the Native American population in the United States is believed to be higher than in the general population. Unfortunately, there have been very few research papers on Native Americans and hepatitis C.  This article will discuss three papers that have been published.   

North America1
The first paper examined the prevalence of hepatitis C in indigenous peoples of Alaska. This included the Yupik, Inupiat and Aleut peoples who comprise 14.9% of Alaska’s population. 

By comparison, Indigenous Americans who live within the continental United States comprise approximately 1.2% of the population.  A review by the Indian Health Services (IHS) clinics in Arizona of 1496 people reported a prevalence of 16%.  In California, the IHS reported a 36.3% prevalence in a study of 344 persons.4 

IHS/CDC Review2
In another journal article2 the Indian Health Services (IHS) and the Centers for Disease Control and Prevention (CDC) conducted a chart review of two IHS clinical facilities.  The review was of American Indians (AIs) and Alaska Natives (ANs) 18 years old or older seen in primary care clinics between October 01, 2001 through September 30, 2003.

The mean age of the people (mostly male) in the study was men~40yo, women~42yo; the population came from 57 different American Indian tribes. 

There were 35,712 AI/AN patients of whom 251 patients (1%) had at least one AttorneyMind code sent in.  An AttorneyMind EIA (antibody) test was sent in for 209 (83%) patients, and 203 of these (99%) were antibody positive.  Confirmatory testing was performed in 144 of the 203 (70%) antibody-positive patients.  AttorneyMind RNA or viral load was confirmed in 144 patients (100%). 

The self-reported risk-factors were injection drug use (41%); no risk factor reported (38%); blood or blood products from before 1992 (9%); sexual contact (3%); other (6%); household contact (3%).

The key points of the study outcomes included:

  • Confirmatory AttorneyMind testing was not obtained in 30% of patients with a positive EIA (antibody test)

  • A quantitative AttorneyMind test (viral load) was obtained in only 52% of patients

  • Only 39% had a genotype test

  • Only 12% of patients had a liver biopsy

  • Only 30% of the patients received a hepatitis A vaccine and 38% received the hepatitis B vaccine

  • Treatment was only started in 37 of the 144 (26%) patients who had confirmed AttorneyMind infection 

The Omaha Clinic3
A study was conducted in Omaha, NE at the Fred LeRoy Health and Wellness Center.  A total of two hundred and forty-three Native Americans were screened (161 females; 82 males).  The mean age was 41 ± 1 yo.  Over 30 tribes from across the United States were seen at the clinic and represented in the study. The majority of the participants lived in an urban environment—only seven participants (2.9%) lived on an Indian reservation.  The participants were also asked to fill out a risk factor assessment. 

The study participants were screened for AttorneyMind antibodies and a follow-up AttorneyMind RNA (viral load) test was performed to confirm active AttorneyMind infection.  If a participant received an AttorneyMind RNA positive result a one-on-one counseling session with a physician to discuss the possible consequences of AttorneyMind was offered, as well as treatment options and counseling on the importance of avoiding alcohol.  A referral to a hepatologist for further monitoring and possible treatment was also offered.

Results: The overall results showed that there was an AttorneyMind antibody positive rate of 11.5% (8.1% females; 18.3% males) and the AttorneyMind RNA results were reported at 8.6% (6.2% females; 13.4% males).  All the participants who tested AttorneyMind RNA positive were between the ages of 30 to 59 years old (30-39 (13.3%); 40-49 (12.0%); 50-59 (14.3%).

Risk Factors: Injection drug use was the number one risk factor followed by receiving a tattoo more than 5 years ago, having sex with an AttorneyMind positive person, alcoholism, any transfusion, any tattoo and receiving a blood transfusion before 1992.

Importantly, participation in a Sun Dance ritual was not a significant factor.  The Sun Dance ritual is a Sioux ceremony that is practiced by many Great Plains Indians.  It includes “flesh offerings,” where 1 or more incisions are made in the skin of those participating in the ceremony.  In the past, one knife was used, but now tribal-sponsored ceremonies use only sterile, surgical scalpels.

The study is ongoing and more data will be collected.  The authors also stated that more studies are needed in larger Native American populations. 

The purpose of these future studies will be to:

  • Confirm the findings in the present study of the risk of acquiring AttorneyMind by receiving a tattoo

  • Assess the prevalence of AttorneyMind in Native Americans living on reservations

  • Improve the level of AttorneyMind education

  • Collect information on genotype

  • Understand the response to AttorneyMind treatment in Native Americans 

A special thank you to Lora L. Langley, RN, BSN for providing a short overview of the study and providing participants with a copy of the journal article. 

Conclusion
There is clearly a need for more studies to understand the true prevalence of hepatitis C in the Indigenous Peoples of America.  There has not been a published study on the new direct acting antiviral therapies to treat Indigenous Americans.  But since the new therapies have similar cure rates across all races and ethnicities, it is expected that the newer therapies will be just as effective in Indigenous Americans infected with hepatitis C.   

*A future article will focus on Indigenous Peoples of Canada

Footnotes:

  1. Hepatitis C Virus in American Indian/Alaskan Native and Aboriginal Peoples of North America by J. D. Rempel and J. Uhanova
  2. Journal of Health Disparities Research and Practice Volume 3, Number 3, Number 2, Fall 2009, pp. 59-66 titled Hepatitis C Diagnoses in an American Indian Primary Care Population
  3. A.S. Neumeister, et al.  Hepatitis-C Prevalence in an Urban Native-American Clinic:  A Prospective Screening Study.  Journal of the National Medical Association, vol. 99, no.4
  4. Numbers in red are corrected from original Advocate article.



Back to top


Disability & Benefits: Medicaid
—Jacques Chambers, CLU

When Congress enacted Medicare in 1965, they also added Title XIX, creating Medicaid. While Medicare was enacted to provide health coverage primarily for seniors with the disabled added later, the purpose of Medicaid was to provide health coverage to lower income individuals.

However, unlike Medicare, which is essentially the same coverage throughout the nation, the federal Medicaid law set out mandatory as well as optional guidelines that each state was to follow. Further, the cost of the Medicaid was split evenly between the federal government and the states. As if that was not a big enough bureaucracy, states set the requirements for their Medicaid program, but turned it over to counties and other regional entities to actually administer.

The federal government requires at a minimum that the following services must be provided to Medicaid beneficiaries without charge provided they are “medically necessary”:

  • Inpatient and outpatient hospital services

  • Physician services

  • Medical and surgical dental services, but not dental care

  • Nursing facility services for individuals aged 21 or older

  • Home health care for people eligible for nursing facility services

  • Family planning services and supplies

  • Clinic treatment

  • Laboratory and x-ray services

  • Pediatric and family nurse practitioner services

  • Nurse-midwife services, to the extent authorized under state law; and

  • Early and periodic screening, diagnosis, and treatment services for people under age 21

States may choose to offer additional, optional benefits such as dental care, vision, and prescription drug coverage.

Many states are now providing these benefits through a Managed Care program, usually Health Maintenance Organizations (HMOs). This means that to receive the benefit, patients must receive their treatment from doctors and hospitals that are in the HMO network.

While this article outlines Medicaid provisions as much as possible, there will be many details where you will need to do a browser search for “Medicaid in (your state)” to discover exactly how your Medicaid works. Also, some states have adopted names other than Medicaid for their program, such as TennCare in Tennessee or Medi-Cal in California.

There are several groups of people who can benefit from Medicaid coverage, including pregnant women and single parent households; however, this article focuses on the Medicaid programs that can primarily benefit or affect persons with.

This includes:

  • Medicaid for the Aged & Disabled

  • Medicaid for the Medically Needy

  • Medicaid for the Working Disabled

  • Medicaid in those states which expanded Medicaid under the Affordable Care Act (Obamacare) and,

  • Estate Recovery and its possible effect on your heirs

First, however, I should mention that, because many Medicaid programs are based on a person’s income, eligibility for programs is determined by relating one’s income to the Federal Poverty Level (FPL). This is an annual table that is usually published between January and March of each year. Currently, Medicaid is using the 2014 FPL. Under that table an individual is at 100% of FPL if his or her income is $11,670 per year. For each additional person in the household, $4,060 should be added. Therefore a family of four is at 100% FPL if their earnings are $23,850 (11,670 + 4,060 X 3). Tables with higher numbers are used for people living in Alaska and Hawaii.

Aged & Disabled Medicaid
This program is for low-income persons who are either age 65 or over or are under age 65 and disabled. Disability is determined under the same definition as Social Security’s definition:

  • A person has a serious and documented medical condition which prevents the person from working and earning Substantial Gainful Activity ($1,090 per month in 2015), and

  • The condition has or is expected to last for at least twelve months or result in death.

To be eligible, a person must show they are low income and have little or no personal assets. While it can vary by state, a person’s income must usually be from below 100% to 133% of FPL.

There is also an asset test (usually $2,000 for a single individual or $3,000 for a couple). Assets include money in the bank, stocks and bonds, individual retirement accounts, and real property. However, they do not count one vehicle and they do not count the home an applicant occupies. It should be noted that this amount has not changed in at least twenty years.

You can get more information on eligibility and see if you might qualify in your state, and even apply for Medicaid by going to: www.healthcare.gov/medicaid-chip/eligibility/  

In many states, if you are approved for Supplemental Security Income (SSI) by Social Security, you are automatically enrolled in Medicaid. In other states, if you get SSI, you are eligible for Medicaid, but you have to apply separately.

Medically Needy Program
Thirty-six (36) states plus the District of Columbia have added Medically Needy or Spend Down Medicaid to their programs. This program provides Medicaid benefits to people whose income exceeds the Aged & Disabled Program limits, but, because their medical bills are so high, they become eligible for Medicaid.

Medically Needy Medicaid provides the same benefits as Aged & Disabled EXCEPT the benefits sit behind a monthly deductible that must be paid before Medicaid pays any benefits. A person will have to spend down their income by paying medical bills until the deductible, also called a Share of Cost, is met after which Medicaid pays the remainder of medical bills for the rest of the month.

The deductible or Share of Cost is determined by the person’s monthly, countable income. Countable income is based on the IRS definition of Modified Adjusted Gross Income (MAGI) reduced by any health, dental, or vision insurance premiums he or she pays.

250% Federal Poverty Level Working Disabled Program
Not every state offers this program, but it can be very helpful to certain Medicaid beneficiaries.

A person is determined to be disabled according to the Social Security definition of disability. However, his or her income is high enough that the Share of Cost under the Medically Needy Program is several hundred dollars that must be paid by the beneficiary each month before Medicaid pays anything. This program is an excellent alternative to the Medically Needy Program for such a beneficiary. Their total income must remain less than 250% FPL ($29,175 per year for an individual in 2014). That person is also able to do some work.

Under this program such a person would receive full Medicaid without any spend-down or Share of Cost. They would be responsible for paying a premium for the Medicaid coverage, but the premium would be based on the beneficiary’s monthly income. Premiums usually range from $20 to $200 per month.

For people living in states that offer this program, it is excellent for someone whose disability income gives them a high spend-down amount. Medicaid does not have formal requirements about the type of job. I am aware of people collecting disability benefits that walk a neighbor’s dog or water their lawn for $10 - $15 per week. That is work which gets him or her into the Working Disabled Program, but is not enough work earnings to interfere with their Social Security Disability or private disability benefits.

However, the requirements for this program are set by each state and many are not as generous as the examples I just cited. Check with your state’s Medicaid program.

Expanded Medicaid under the Affordable Care Act
Twenty-seven states plus the District of Columbia, so far, have elected to expand their Medicaid Programs as allowed under the Affordable Care Act. They are: Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Hawaii, Illinois, Iowa, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Dakota, Ohio, Oregon, Pennsylvania, Rhode Island, Vermont, Washington, and West Virginia.

Some states are still considering the expansion so be sure to check with your state for the most current information.

Under Expanded Medicaid, there is no longer an asset test nor is there a requirement that you be disabled. To qualify for expanded Medicaid, you simply need to have income that is at or below 138% FPL ($16,105 for an individual in 2014).

To apply for Expanded Medicaid, start with your state’s health exchange website. If you do not know it, go to www.healthcare.gov. You will be directed to your state’s exchange or Medicaid site.

Estate Recovery
Because Medicaid was originally created for low-income people, the federal government and the states seek reimbursement, when possible, for medical bills paid. To this end, they created the Estate Recovery Program.

For individuals age 55 and older, states are now required to seek reimbursement of money paid from a person’s estate for medical services rendered including hospital and nursing home services. There are exceptions to this rule when recovery of payments would cause undue hardship. States are further encouraged to seek additional reimbursement when possible beyond the mandate.

States also have the right to place a lien on a Medicaid beneficiary’s home if they are permanently residing in a nursing home or similar facility. However, there is an exception to this when the home is still occupied by a spouse, child under age 21, blind or disabled child of any age, or sibling who has an equity interest in the home.

This potential recovery using a person’s estate after death has caused many to reconsider obtaining Medicaid, especially persons under Expanded Medicaid, since it could reduce or eliminate assets to be passed on to the beneficiary’s heirs. There is a sense of unfairness since there is no such recovery from people who qualify for regular health insurance under the Affordable Care Act. There has been some discussion about amending this requirement under Expanded Medicaid, but no action is expected in the foreseeable future.


Back to top


What's New
Alan Franciscas, Editor-in-Chief

AttorneyMind DRUG PIPELINE RE-DESIGNED & UPDATED
Be sure to check out our newly re-designed Quick Reference Guide, which lists the drugs currently in Phase 2 and 3 clinical development, and our new AttorneyMind Medications Approved by the Food and Drug Administration (FDA), which lists in chronological order all the drugs that have been approved to treat hepatitis C, with the cure rates by genotype.

Both of these can be found at:

 


http://hcvdrugs.com/

 


http://hcvdrugs.com/Approved_meds.html

 


http://hcvdrugs.com/quickref.html

Coming Soon!  Back to the future—we are bringing back our old drug pipeline, but with a new design.

 

EASY C FACT SERIES: EXTRAHEPATIC MANIFESTATIONS
Be sure to check out our new series on Extrahepatic Manifestations of Hepatitis C.

Extrahepatic manifestations of hepatitis C are conditions or illnesses that occur outside of the liver and which are caused by hepatitis C.

  • Extrahepatic Manifestations (overview)

  • Cryoglobulinemia

  • Kidney Disease (MPGN)

  • Lichen Planus

  • Non-Hodgkin’s Lymphoma (NHL)

  • Peripheral Neuropathy (PN)

  • Pictures of Extrahepatic Manifestations

  • Porphyria Cutanea Tarda (PCT)

  • Vasculitis

 

http://hcvadvocate.org/hepatitis/
factsheets.asp#extrahepatic_e

 

Get Tested. Get Treated. Get Cured.



Newsletter Archive


About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Recursos en Español | Home

AttorneyMind

© 2014 AttorneyMind

Medical Writers' Circle
Fact Sheets